Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

INTRODUCTION: Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with psoriasis progress to PsA. In most cases, psoriasis precedes synovio-entheseal inflammation by an average of...

Descripción completa

Detalles Bibliográficos
Autores principales: Haberman, Rebecca H, MacFarlane, Katrina A, Catron, Sydney, Samuels, Jonathan, Blank, Rebecca B, Toprover, Michael, Uddin, Zakwan, Hu, Jiyuan, Castillo, Rochelle, Gong, Cinty, Qian, Kun, Piguet, Vincent, Tausk, Francisco, Yeung, Jensen, Neimann, Andrea L, Gulliver, Wayne, Thiele, Ralf G, Merola, Joseph F, Ogdie, Alexis, Rahman, Proton, Chakravarty, Soumya D, Eder, Lihi, Ritchlin, C T, Scher, Jose U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791418/
https://www.ncbi.nlm.nih.gov/pubmed/36564123
http://dx.doi.org/10.1136/bmjopen-2022-063650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791418/
https://www.ncbi.nlm.nih.gov/pubmed/36564123
http://dx.doi.org/10.1136/bmjopen-2022-063650

Ejemplares similares